323. Measuring the Prevalence of Multidrug Resistant Acinetobacter (MDRA) Using OXA 23 and OXA 51 Gene Identification in Healthcare Facilities (HCF) in Washington DC
Session: Poster Abstract Session: HAI: Multi Drug Resistant Gram Negatives
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • 323 IDWkMDRA.pdf (734.3 kB)
  • Background: Multidrug resistance among Acinetobacterinfections reported in healthcare-associated infections through the National Healthcare Safety Network (NHSN) decreased by 34% in the South Atlantic region between 2011 and 2014. NHSN data were largely from acute care hospitals and do not measure colonization rates, resistance in long term care facilities (LTCFs), nor infections that are not healthcare-associated. MDRA is classified as an urgent threat by the Centers for Disease Control and Prevention. A collaborative of HCFs conducted a point prevalence study to determine a baseline in Washington, DC.

    Methods: The study was designed primarily to measure the prevalence of carbapenem-resistant Enterobacteriaceae in DC HCFs. Samples were also evaluated using the Acuitas® MDRO gene test (OpGen) that detects the OXA 23 and OXA 51 genes, commonly associated with MDRA. We assessed 2,216 patients from 16 HCFs (all 8 acute care hospitals (AH); 1 inpatient rehabilitation hospital (IRH), and 7 long term care facilities (LTCF). LTCFs included 5 skilled nursing facilities (SNF) and 2 long term acute care facilities (LTAC]). A total of 1021 patients met inclusion criteria and consented to participate.

    Results: Overall MDRA point prevalence rate (PR) was 6.6%. The PR for AHs, IRH, and LTCFs were 3.7, 0.0, and 16.4, respectively [Table 1]. OXA 23, a gene associated with carbapenem-resistance in Acinetobacterwas detected in 0.8% of samples from AHs (0.0-2.0%), and from 4.9% of samples from LTCFs (0.0-15.4) [p<0.0001].

    Table 1

    Prevalence OXA-23 and OXA 51 Genes(MDRA) – Percent Positive

    Prevalence Ratio (PR) and Confidence Interval (CI) Comparing Location Type to Total

    Location

    Type

    n facilities

    n patients

    targeted

    n samples

    % sampled

    n MDRA

    % MDRA

    Range % MDRA

    MDRA

    PR

     

    MDRA

    PR

    CI

    AH

    8

    1580

    725

    45.9

    27

    3.7

    0.0-5.1

    0.3

    0.2-0.4

    p<0.00001

    LTCF

    7

    543

    244

    44.8

    40

    16.4

    0.0-47.1

    4.7

    3.0-7.5

    p<0.00001

    IRH

    1

    93

    52

    55.9

    0

    0.0

    -

    -

    -

    Total

    16

    2216

    1021

    46.1

    67

    6.6

    0.0-47.1

    Conclusion: This study showed a significantly greater prevalence of MDRA in LTCFs in the setting of decreasing HAIs due to MDRA in AHs. Although the reason for the different PR is unknown, DC HCFs can use these data to collaborate for improved information on patients’ resistance profiles as they traverse the continuum of care.

    Jacqueline Reuben, MHS1, Nancy Donegan, MPH2, Jo Anne Nelson, DC3, Brendan Sinatro, MPH3, Morris Blaylock, Ph.D.4 and Kimary Harmon, MBA, MPH5, (1)Center for Policy, Planning and Evaluation, DC Department of Health, Washington, DC, (2)District of Columbia Hospital Association, Alexandria, VA, (3)District of Columbia Hospital Association, Washington, DC, (4)Washington DC Public Health Laboratory, Department of Forensic Sciences, Washington, DC, (5)Public Health Laboratory, Department of Forensic Science, Washington, DC

    Disclosures:

    J. Reuben, None

    N. Donegan, OpGen: Collaborator , Research support

    J. A. Nelson, None

    B. Sinatro, OpGen: Collaborator , Research support

    M. Blaylock, None

    K. Harmon, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.